Letter of intent for ChronSeal® has been signed with Japan’s leading dermatology company
Through Tripep’s partner Kringle Pharma a letter of intent has been signed with the Japanese specialty pharma company Maruho regarding ChronSeal®, Tripep’s and Kringle Pharma’s co-owned product for the treatment of chronic leg wounds. The letter of intent gives Maruho a first right to evaluate the results from the ongoing phase I/II study and to negotiate the marketing rights for the Japanese market.
“We are very pleased indeed that Maruho, Japan’s leading dermatology pharmaceutical company shows a keen interest in ChronSeal®. This is a clear acknowledgment of the commercial value of the product”, says Jan Nilsson, CEO of Tripep.
ChronSeal® is a cream based on HGF (Hepatocyte Growth Factor) for the treatment of chronic leg wounds, a problem which is rapidly growing in the ageing population of the Western world. Together with its partners Tripep has developed a new formulation which results in a controlled release of HGF and in addition it enables the use of ChronSeal® without having to combine it with antibiotics. This, in turn, avoids development of antibiotic resistance, another rapidly growing problem. An application for a patent pertaining to an antibiotic-free formulation of ChronSeal® was filed in the US in January 2008. As has earlier been announced a clinical multi center phase I/II study on ChronSeal® has just has began, approved by the Medical Products Agencies in Sweden and Norway.
More than four million people in the US and Europe are currently suffering from chronic leg wounds which corresponds to a market value of approximately SEK 36 billion. Accordingly, the medical need is considerable and the growth rate is high, factors that are expected to provide ChronSeal® with substantial commercial potential.
For more information, please contact:
Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80,
Mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se
Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313,
Mobil phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se
About Tripep
Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal® and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company’s website:
www.tripep.se.
In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.